

| | MYC | | |
|------------------------------|----------------------------|--|--------------------------|
| | PYCR1 | ALDH18A1 | GLS |
| mRNA | | | |
| All cases | -0.058 (0.010) | -0.221 (2.3x10⁻²³) | 0.038 (0.092) |
| PAM50 | | | |
| Luminal A | -0.133 (0.0003) | -0.339 (9.8x10⁻²¹) | -0.017 (0.659) |
| Luminal B | 0.124 (0.006) | -0.070 (0.123) | 0.052 (0.248) |
| Basal | 0.094 (0.088) | 0.023 (0.677) | -0.072 (0.193) |
| HER2 | 0.030 (0.646) | -0.201 (0.002) | 0.026 (0.284) |
| Normal | -0.335 (0.000001) | -0.395 (7.5x10⁻⁹) | -0.148 (0.037) |
| Protein | | | |
| All cases | -0.011 (0.772) | 0.394 (1.8x10⁻³³) | 0.148 (0.00002) |
| IHC molecular classes | | | |
| ER+/HER2- Low Proliferation | 0.166 (0.048) | 0.253 (0.001) | 0.124 (0.111) |
| ER+/HER2- High Proliferation | 0.156 (0.013) | 0.221 (0.0001) | 0.145 (0.015) |
| Triple Negative | 0.149 (0.074) | 0.378 (3.9x10⁻⁷) | 0.292 (0.0003) |
| HER2+ | -0.060 (0.551) | 0.492 (2.8x10⁻⁸) | 0.094 (0.329) |

Table 4. Gln-Pro enzymes and MYC expression in breast cancer molecular subtypes